During the past decade, Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 3 clinical trials were completed, i.e. on average, 27.3% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III" #1 sponsor was "Hoffmann-La Roche" with 4 trials, followed by "University of Heidelberg Medical Center" with 2 trials sponsored, "Universität des Saarlandes" with 2 trials sponsored, "GWT-TUD GmbH" with 1 trials sponsored and "Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III" #1 collaborator was "Novartis Pharmaceuticals" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Celltrion Healthcare Co., LTD" with 1 trials as a collaborator, "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 1 trials as a collaborator and "German Low Grade Lymphoma Study Group" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III" are "Multiple Myeloma" (2 trials), "Acute Myeloid Leukemia" (1 trials), "Acute Myeloid Leukemia (AML)" (1 trials), "Advanced Follicular Lymphoma" (1 trials) and "CD20+ Aggressive B-Cell Lymphoma" (1 trials). Many other conditions were trialed in "Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III" in a lesser frequency.

Most popular intervention types in "Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III" are "Drug" (14 trials), "Other" (2 trials), "Device" (1 trials), "Genetic" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Rituximab" (4 trials), "Lenalidomide" (3 trials), "Bendamustine" (2 trials), "Bortezomib" (2 trials) and "Cyclophosphamide" (2 trials). Other intervention names were less common.

The vast majority of trials in "Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III" are 15 trials for "All" genders.

Currently, there are NaN active trials in "Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III". undefined are not yet recruiting, 3 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".